Document Detail


Methotrexate for rheumatoid arthritis patients who are on hemodialysis.
MedLine Citation:
PMID:  21833520     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Methotrexate (MTX) can be toxic to patients suffering from end stage renal disease (ESRD) on hemodialysis even at low doses. This increase in toxicity is more notable in terms of bone marrow suppression in the form of pancytopenia. Many methods of elimination including dialysis itself have been proven ineffective, and alternate treatments with anti-TNF alpha blockers can be considered.
Authors:
Hasanein Al-Hasani; Euthalia Roussou
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-7-22
Journal Detail:
Title:  Rheumatology international     Volume:  -     ISSN:  1437-160X     ISO Abbreviation:  -     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-8-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8206885     Medline TA:  Rheumatol Int     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Barts and The London School of Medicine and Dentistry, Turner Street, London, E1 2AD, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, dia...
Next Document:  Pulmonary capillaritis leading to alveolar hemorrhage in a juvenile idiopathic arthritis patient: fi...